Effect of conversion from cyclosporine A (CSA) to tacrolimus (FK 506) on cardiovascular risk factors in liver transplant recipients.

被引：0
|
作者：
Canzanello, VJ [1 ]
Schwartz, LL [1 ]
Taler, SJ [1 ]
Textor, SC [1 ]
Atwood, G [1 ]
Porayko, MK [1 ]
Wiesner, RH [1 ]
Krom, RAF [1 ]
机构：
[1] MAYO CLIN,ROCHESTER,MN
来源：
HEPATOLOGY | 1997年 / 26卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1443 / 1443
页数：1
相关论文
共 50 条
  • [21] Improvement of cardiovascular risk factors in heart transplant recipients after conversion from cyclosporine to tacrolimus:: A role of the TGF-β system
    van Riemsdijk, IC
    Baan, CC
    Balk, AHMM
    Vantrimpont, PMAJ
    Maat, LPWM
    Weimar, W
    [J]. TRANSPLANTATION PROCEEDINGS, 2002, 34 (05) : 1864 - 1865
  • [22] Dose Conversion Factor Between Cyclosporine and Tacrolimus in Pediatric Heart Transplant Recipients.
    Notaro, E.
    Brown, L.
    Albers, E.
    Law, S.
    Law, Y.
    Kemna, M.
    [J]. TRANSPLANTATION, 2014, 98 : 235 - 235
  • [23] Improvement in cardiovascular risk profile in longterm cyclosporine-based liver transplant recipients.
    Prieto, M
    García-Herola, A
    Machancoses, A
    Berenguer, M
    Carrasco, D
    Mir, J
    Berenguer, J
    [J]. HEPATOLOGY, 1998, 28 (04) : 355A - 355A
  • [24] Conversion of cyclosporine (neoral;: CsA) to mycophenolate mofetil (MMF) in stable renal transplant recipients.
    Schrama, YC
    Hené, RJ
    Boer, P
    Koomans, HA
    [J]. KIDNEY INTERNATIONAL, 1999, 55 (04) : 1625 - 1626
  • [25] Steroid withdrawal in tacrolimus (FK506)-treated pediatric liver transplant recipients
    McKee, M
    Mattei, P
    Schwarz, K
    Wise, B
    Colombani, P
    [J]. JOURNAL OF PEDIATRIC SURGERY, 1997, 32 (07) : 973 - 975
  • [26] The effect of cyclosporine versus tacrolimus on long-term renal function in liver transplant recipients.
    Pham, PTT
    Wilkinson, AH
    Danovitch, GM
    Pham, PCT
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 649A - 649A
  • [27] METABOLIC EFFECTS OF CYCLOSPORINE-A AND FK-506 IN LIVER-TRANSPLANT RECIPIENTS
    KRENTZ, AJ
    DOUSSET, B
    MAYER, D
    MCMASTER, P
    BUCKELS, J
    CRAMB, R
    SMITH, JM
    NATTRASS, M
    [J]. DIABETES, 1993, 42 (12) : 1753 - 1759
  • [28] Occurrence of gammopathies and lymphoproliferative disorders in liver transplant recipients randomized to tacrolimus (FK506)- or cyclosporine-based immunosuppression
    Pham, H
    Lemoine, A
    Salvucci, M
    Azoulay, D
    Frenoy, N
    Samuel, D
    Reynes, M
    Bismuth, H
    Debuire, B
    [J]. LIVER TRANSPLANTATION AND SURGERY, 1998, 4 (02): : 146 - 151
  • [29] Dose adjustment and cost of itraconazole prophylaxis in lung transplant recipients receiving cyclosporine and Tacrolimus (FK 506)
    Kramer, MR
    Merin, G
    Rudis, E
    Bar, I
    Nesher, T
    Bublil, M
    Milgalter, E
    [J]. TRANSPLANTATION PROCEEDINGS, 1997, 29 (06) : 2657 - 2659
  • [30] Effect of conversion from cyclosporine to tacrolimus on lipid profiles in renal transplant recipients
    Colak, T
    Karakayali, H
    Yagmurdur, MC
    Moray, G
    [J]. TRANSPLANTATION PROCEEDINGS, 2002, 34 (06) : 2081 - 2082
12345